These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. McCoy KD; Hermans IF; Fraser JH; Le Gros G; Ronchese F J Exp Med; 1999 Apr; 189(7):1157-62. PubMed ID: 10190907 [TBL] [Abstract][Full Text] [Related]
9. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors. Khan SM; Desai R; Coxon A; Livingstone A; Dunn GP; Petti A; Johanns TM J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543376 [TBL] [Abstract][Full Text] [Related]
10. Autophagy protein ATG5 regulates CD36 expression and anti-tumor MHC class II antigen presentation in dendritic cells. Oh DS; Lee HK Autophagy; 2019 Dec; 15(12):2091-2106. PubMed ID: 30900506 [TBL] [Abstract][Full Text] [Related]
11. Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response. Jin C; Ali A; Iskantar A; Fotaki G; Wang H; Essand M; Karlsson-Parra A; Yu D Oncoimmunology; 2022; 11(1):2099642. PubMed ID: 35859733 [TBL] [Abstract][Full Text] [Related]
12. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365 [TBL] [Abstract][Full Text] [Related]
13. CD4 Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929 [TBL] [Abstract][Full Text] [Related]
14. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
15. CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Chen X; Shao Q; Hao S; Zhao Z; Wang Y; Guo X; He Y; Gao W; Mao H Oncotarget; 2017 Feb; 8(8):13703-13715. PubMed ID: 28099147 [TBL] [Abstract][Full Text] [Related]
16. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864 [TBL] [Abstract][Full Text] [Related]
17. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358 [TBL] [Abstract][Full Text] [Related]
18. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163 [TBL] [Abstract][Full Text] [Related]
19. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Redmond WL; Linch SN; Kasiewicz MJ Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278 [TBL] [Abstract][Full Text] [Related]
20. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4 Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]